These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35716975)

  • 41. Spherical agglomerates of lactose as potential carriers for inhalation.
    Zellnitz S; Lamešić D; Stranzinger S; Pinto JT; Planinšek O; Paudel A
    Eur J Pharm Biopharm; 2021 Feb; 159():11-20. PubMed ID: 33358941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of two twin-screw extruders for continuous granulation.
    Djuric D; Van Melkebeke B; Kleinebudde P; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2009 Jan; 71(1):155-60. PubMed ID: 18678245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dry powder inhalers: study of the parameters influencing adhesion and dispersion of fluticasone propionate.
    Le VN; Hoang Thi TH; Robins E; Flament MP
    AAPS PharmSciTech; 2012 Jun; 13(2):477-84. PubMed ID: 22399285
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1326-30. PubMed ID: 11605663
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aerosol dispersion of respirable particles in narrow size distributions using drug-alone and lactose-blend formulations.
    Louey MD; Van Oort M; Hickey AJ
    Pharm Res; 2004 Jul; 21(7):1207-13. PubMed ID: 15290861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Focusing on powder processing in dry powder inhalation product development, manufacturing and performance.
    Stegemann S; Faulhammer E; Pinto JT; Paudel A
    Int J Pharm; 2022 Feb; 614():121445. PubMed ID: 34998921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
    Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
    Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers.
    Flament MP; Leterme P; Gayot A
    Int J Pharm; 2004 May; 275(1-2):201-9. PubMed ID: 15081150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dry powder inhaler performance of spray dried mannitol with tailored surface morphologies as carrier and salbutamol sulphate.
    Mönckedieck M; Kamplade J; Fakner P; Urbanetz NA; Walzel P; Steckel H; Scherließ R
    Int J Pharm; 2017 May; 524(1-2):351-363. PubMed ID: 28347847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Entrainment of lactose inhalation powders: a study using laser diffraction.
    Watling CP; Elliott JA; Cameron RE
    Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of a new inhalable thymopentin formulation.
    Wang L; Zhang Y; Tang X
    Int J Pharm; 2009 Jun; 375(1-2):1-7. PubMed ID: 19443146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The influence of high shear mixing on ternary dry powder inhaler formulations.
    Hertel M; Schwarz E; Kobler M; Hauptstein S; Steckel H; Scherließ R
    Int J Pharm; 2017 Dec; 534(1-2):242-250. PubMed ID: 29051120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance tuning of particle engineered mannitol in dry powder inhalation formulations.
    Hertel N; Birk G; Scherließ R
    Int J Pharm; 2020 Aug; 586():119592. PubMed ID: 32622814
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation.
    Giry K; Péan JM; Giraud L; Marsas S; Rolland H; Wüthrich P
    Int J Pharm; 2006 Sep; 321(1-2):162-6. PubMed ID: 16797150
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dry powders for oral inhalation free of lactose carrier particles.
    Healy AM; Amaro MI; Paluch KJ; Tajber L
    Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of drug alone and carrier-based GLP-1 dry powder inhaler formulations.
    Babenko M; Alany RG; Calabrese G; Kaialy W; ElShaer A
    Int J Pharm; 2022 Apr; 617():121601. PubMed ID: 35181460
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-line quantification of drug and excipients in cohesive powder blends by near infrared spectroscopy.
    Liew CV; Karande AD; Heng PW
    Int J Pharm; 2010 Feb; 386(1-2):138-48. PubMed ID: 19922776
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of budesonide nanocluster dry powder aerosols: preformulation.
    El-Gendy N; Selvam P; Soni P; Berkland C
    J Pharm Sci; 2012 Sep; 101(9):3434-44. PubMed ID: 22623018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.